Razelle Kurzrock MD

Chief, Division of Hematology & Oncology Sr. Deputy Center Director, Clinical Science, Director, Center for Personalized Cancer Therapy and Clinical Trials Office, UC San Diego Moores Cancer Center

Join to View Full Profile

9200 W Wisconsin AveMilwaukee, WI 53226
Phone+1 414-805-0505
Fax+1 414-805-6808

Education & Training

University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1982 - 1983
Tulane UniversityResidency, Internal Medicine, 1979 - 1981
University of Toronto Faculty of MedicineClass of 1978

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1986 - Present
TX State Medical License 1984 - 2026
CA State Medical License 2014 - 2025
WI State Medical License 2022 - 2025
LA State Medical License 1979 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 1997

Clinical Trials

Amifostine in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 1997 Jun 05
Completed
Phase 2
Tipifarnib in Treating Patients With Myelodysplastic Syndromes Start of enrollment: 2002 Jun 01
Completed
Phase 1
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron Start of enrollment: 2001 Feb 01
Terminated
Phase 2
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies Start of enrollment: 1994 Sep 06
Completed
Phase 2
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Start of enrollment: 1990 May 08
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer Start of enrollment: 2002 May 01
Completed
Phase 2
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer Start of enrollment: 2005 Oct 01
Completed
Phase 1
Study of Atiprimod Treatment for Patients With Advanced Cancer Start of enrollment: 2005 Mar 01
Terminated
Phase 1
Azacytidine and Valproic Acid in Patients With Advanced Cancers Start of enrollment: 2005 May 01
Completed
Phase 1
Phase I Trial of ZIO-101 in Patients With Solid Tumors Start of enrollment: 2005 May 01
Completed
Phase 1
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01) Start of enrollment: 2007 May 01
Completed
Phase 1
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy Start of enrollment: 2008 Jan 25
Completed
Phase 1
Study of Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2008 Sep 01
Completed
Phase 1
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients Start of enrollment: 2009 Apr 01
Terminated
Phase 1, Phase 2
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2010 Jun 01
Completed
Phase 1
Temsirolimus In Phase 0 Start of enrollment: 2010 Aug 01
Completed
Early Phase 1
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib Start of enrollment: 2012 Dec 01
Withdrawn
Phase 1
Survival Prolongation by Rationale Innovative Genomics Start of enrollment: 2017 Nov 29
Terminated
Phase 1, Phase 2
The Registry of Oncology Outcomes Associated with Testing and Treatment Start of enrollment: 2021 May 05
COMPLETED
Join now to see all

Publications & Presentations

PubMed

1 citations
Nectin-4 expression patterns and therapeutics in oncology.
Mina Nikanjam, Judith Pérez-Granado, Mark Gramling, Bruno Larvol, Razelle Kurzrock
Cancer Letters. 2025-07-10
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.
Alberto Hernando-Calvo, Razelle Kurzrock, Nadia Saoudi Gonzalez, Shai Magidi, Catherine Bresson
Oncotarget. 2025-06-17
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
Funda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney, Charles Swanton, David R Spigel
Clinical Cancer Research. 2025-06-13

Journal Articles

International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis Is an Independent Predictor of Progression-Free Survival
Andrew M Lowy, Kaitlyn J Kelly, Joel M Baumgartner, Lisa Tran, Razelle Kurzrock, Annals of Surgical Oncology

Abstracts/Posters